Abstract
Few well-controlled, randomized studies have compared therapeutic agents for cutaneous lesions of lupus erythematosus (LE). Antimalarial agents such as chloroquine are FDA-approved and considered effective but can be toxic, particularly with chronic use. An equally effective but nontoxic alternative would be a welcome addition to our therapeutic armamentarium. Clofazimine is approved for the treatment of leprosy and erythema nodosum leprosum but has limited distribution in the U.S. These authors compared clofazimine with chloroquine for treating 33 patients …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
